Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154996 · ClinicalTrials.gov registry record · Phase 1
Chronic Convection Enhanced Delivery of Topotecan
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03154996: Completed Phase 1 study, sponsored by Columbia University.
NCT03154996 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03154996, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary goal of this study is to establish, for the first time, safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients with recurrent high grade glioma (HGG). Secondary objectives will include determination of topotecan (TPT) distribution and radiographic tumor response with prolonged continuous intracerebral convection-enhanced delivery (CED).
Primary Outcome
This is designed to measure the safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients.
Interventions
- DRUG Topotecan
- DRUG Gadolinium
- DEVICE Synchromed II infusion pumps
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2021-08-20 |
| Phase | Phase 1 |
What the finished NCT03154996 record still lists
NCT03154996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Topotecan is the first listed.
NCT03154996 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03154996 about?
NCT03154996 is a clinical study titled "Chronic Convection Enhanced Delivery of Topotecan". The primary goal of this study is to establish, for the first time, safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients with recurrent high grade glioma (HGG). Secondary objectives will include determination of topotecan (TPT) distribution and radiographic tumo...
What is the current status of trial NCT03154996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-01-18. Estimated completion is 2021-08-20.
What interventions are being tested in trial NCT03154996?
The interventions under investigation include: Topotecan (DRUG), Gadolinium (DRUG), Synchromed II infusion pumps (DEVICE).
Who is sponsoring clinical trial NCT03154996?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03154996's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI